-
Je něco špatně v tomto záznamu ?
Past use of metformin is associated with increased risk of myelodysplastic syndrome development in diabetes mellitus patients: a cross-sectional study of 54,869 patients
T. Hellou, G. Dumanis, S. Portugez, AP. Goncharov, E. Trodler, A. Stern, I. Carlebach, O. Kahlon, MA. Jwella, E. Nimer, A. Athamna, A. Berman, G. Segal, RK. Lerner
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
NLK
BioMedCentral
od 2012-12-01
BioMedCentral Open Access
od 2001
Directory of Open Access Journals
od 2012
Free Medical Journals
od 2012
PubMed Central
od 2012
Europe PubMed Central
od 2012
ProQuest Central
od 2015-01-01
Open Access Digital Library
od 2012-01-01
Open Access Digital Library
od 2012-01-01
Medline Complete (EBSCOhost)
od 2012-08-13
Health & Medicine (ProQuest)
od 2015-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2012
Springer Nature OA/Free Journals
od 2012-12-01
- MeSH
- diabetes mellitus epidemiologie chemicky indukované MeSH
- dospělí MeSH
- hypoglykemika * terapeutické užití škodlivé účinky MeSH
- lidé středního věku MeSH
- lidé MeSH
- metformin * terapeutické užití škodlivé účinky MeSH
- myelodysplastické syndromy * epidemiologie chemicky indukované MeSH
- průřezové studie MeSH
- rizikové faktory MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Myelodysplastic Syndrome (MDS) is a devastating hematologic malignancy associated with advanced age. Diabetes Mellitus (DM) is one of the most common morbidities worldwide, with metformin serving as the first line therapy for several decades. However, the potential association between previous metformin use and the risk of developing MDS remains uncertain. METHODS: This cross-sectional study addressed the possible association between prior metformin use in DM patients and the subsequent development of MDS. RESULTS: Data from 54,869 DM patients was retrieved from their medical records from a tertiary medical center. Of these, 20,318 patients had been exposed at some point in time to metformin, with 133 (0.7%) subsequently developing MDS. In contrast, among 34,551 DM patients with no prior exposure to metformin, only 154 (0.4%) developed MDS later in life. The Odds Ratio (OR) for MDS development amongst metformin users compared to the entire study population was 1.48 (95% CI 1.17-1.86; p = 0.001). A multivariate analysis adjusting for gender, age, congestive heart failure and chronic kidney disease, past exposure to metformin remained an independent risk factor for MDS development (OR = 1.6, 95% CI 1.26-2.03; p < 0.001). CONCLUSION: Previous exposure to metformin amongst DM patients is associated with an increased risk for MDS development later in life. This is a preliminary, cross-sectional study that show that larger studies in variable MDS patient populations are warranted.
Adelson School of Medicine Ariel University Ariel 4070000 Israel
Dan Petah Tikvah District at Clalit Health Service Petah Tikvah Israel
Education Authority Chaim Sheba Medical Center Tel Hashomer Ramat Gan Israel
Faculty of Health Science and Medicine Tel Aviv University Tel Aviv Israel
Faculty of Medicine and Dentistry Palacký University in Olomouc Olomouc 77900 Czech Republic
Faculty of Medicine Kharkiv National Medical University Kharkiv Ukraine
Hematology Division Chaim Sheba Medical Center Ramat Gan Israel
Internal Medicine Division Sheba Medical Center Ramat Gan Israel
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25009794
- 003
- CZ-PrNML
- 005
- 20250429135449.0
- 007
- ta
- 008
- 250415s2025 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s40360-025-00882-7 $2 doi
- 035 __
- $a (PubMed)40016854
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Hellou, Tamer $u Hematology Division, Chaim Sheba Medical Center, Ramat Gan, Israel $u Faculty of Health Science and Medicine, Tel-Aviv University, Tel-Aviv, Israel
- 245 10
- $a Past use of metformin is associated with increased risk of myelodysplastic syndrome development in diabetes mellitus patients: a cross-sectional study of 54,869 patients / $c T. Hellou, G. Dumanis, S. Portugez, AP. Goncharov, E. Trodler, A. Stern, I. Carlebach, O. Kahlon, MA. Jwella, E. Nimer, A. Athamna, A. Berman, G. Segal, RK. Lerner
- 520 9_
- $a BACKGROUND: Myelodysplastic Syndrome (MDS) is a devastating hematologic malignancy associated with advanced age. Diabetes Mellitus (DM) is one of the most common morbidities worldwide, with metformin serving as the first line therapy for several decades. However, the potential association between previous metformin use and the risk of developing MDS remains uncertain. METHODS: This cross-sectional study addressed the possible association between prior metformin use in DM patients and the subsequent development of MDS. RESULTS: Data from 54,869 DM patients was retrieved from their medical records from a tertiary medical center. Of these, 20,318 patients had been exposed at some point in time to metformin, with 133 (0.7%) subsequently developing MDS. In contrast, among 34,551 DM patients with no prior exposure to metformin, only 154 (0.4%) developed MDS later in life. The Odds Ratio (OR) for MDS development amongst metformin users compared to the entire study population was 1.48 (95% CI 1.17-1.86; p = 0.001). A multivariate analysis adjusting for gender, age, congestive heart failure and chronic kidney disease, past exposure to metformin remained an independent risk factor for MDS development (OR = 1.6, 95% CI 1.26-2.03; p < 0.001). CONCLUSION: Previous exposure to metformin amongst DM patients is associated with an increased risk for MDS development later in life. This is a preliminary, cross-sectional study that show that larger studies in variable MDS patient populations are warranted.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a metformin $x terapeutické užití $x škodlivé účinky $7 D008687
- 650 12
- $a myelodysplastické syndromy $x epidemiologie $x chemicky indukované $7 D009190
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a průřezové studie $7 D003430
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a hypoglykemika $x terapeutické užití $x škodlivé účinky $7 D007004
- 650 _2
- $a diabetes mellitus $x epidemiologie $x chemicky indukované $7 D003920
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a dospělí $7 D000328
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Dumanis, Guy $u Adelson School of Medicine, Ariel University, Ariel, 4070000, Israel
- 700 1_
- $a Portugez, Shir $u Silesia Medical University, Katowice, Poland
- 700 1_
- $a Goncharov, Aviv Philip $u Faculty of Medicine and Dentistry, Palacký University in Olomouc, Olomouc, 77900, Czech Republic
- 700 1_
- $a Trodler, Eden $u Faculty of Medicine and Dentistry, Palacký University in Olomouc, Olomouc, 77900, Czech Republic
- 700 1_
- $a Stern, Asaf $u Faculty of Medicine and Dentistry, Palacký University in Olomouc, Olomouc, 77900, Czech Republic
- 700 1_
- $a Carlebach, Imanuel $u Faculty of Medicine and Dentistry, Palacký University in Olomouc, Olomouc, 77900, Czech Republic
- 700 1_
- $a Kahlon, Omer $u Faculty of Medicine and Dentistry, Palacký University in Olomouc, Olomouc, 77900, Czech Republic
- 700 1_
- $a Jwella, Maysan Abu $u Faculty of Medicine and Dentistry, Palacký University in Olomouc, Olomouc, 77900, Czech Republic
- 700 1_
- $a Nimer, Ekram $u Faculty of Medicine, Kharkiv National Medical University, Kharkiv, Ukraine
- 700 1_
- $a Athamna, Ahlam $u Internal Medicine Division, Sheba Medical Center, Ramat Gan, Israel
- 700 1_
- $a Berman, Aya $u Dan Petah-Tikvah District at Clalit Health Service, Petah-Tikvah, Israel
- 700 1_
- $a Segal, Gad $u Faculty of Health Science and Medicine, Tel-Aviv University, Tel-Aviv, Israel. gad.segal@sheba.health.gov.il $u Education Authority, Chaim Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel. gad.segal@sheba.health.gov.il
- 700 1_
- $a Lerner, Reut Kassif $u Faculty of Health Science and Medicine, Tel-Aviv University, Tel-Aviv, Israel $u Department of Pediatric Intensive Care, The Edmond and Lily Safra Children's Hospital, at Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
- 773 0_
- $w MED00195156 $t BMC pharmacology & toxicology $x 2050-6511 $g Roč. 26, č. 1 (2025), s. 45
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40016854 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429135444 $b ABA008
- 999 __
- $a ok $b bmc $g 2311279 $s 1246875
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 26 $c 1 $d 45 $e 20250227 $i 2050-6511 $m BMC pharmacology & toxicology $n BMC Pharmacol Toxicol $x MED00195156
- LZP __
- $a Pubmed-20250415